Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis

Leukemia volume 30, pages 1788–1792 (2016)Cite this article

Subjects

Acute myeloid leukemia (AML) is a heterogeneous hematologic disease characterized by the accumulation of immature myeloid cells. Despite the recent advances in the treatment of AML, drug resistance and disease relapse remain a substantial clinical problem.

AML cells are characterized by their recurrent contact with the stromal microenvironment in the bone marrow (BM).1 This interplay between the BM stroma and AML cells protects malignant cells from spontaneous apoptosis, promotes proliferation and drug resistance. Increasing evidence suggests that this stromal refuge has a pivotal role in paving the way for disease relapse.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Ayala F, Dewar R, Kieran M, Kalluri R . Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 2009; 23: 2233–2241.

    Article  CAS  Google Scholar 

  2. Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012; 119: 3917–3924.

    Article  CAS  Google Scholar 

  3. Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004; 64: 2817–2824.

    Article  CAS  Google Scholar 

  4. Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.

    Article  CAS  Google Scholar 

  5. Chen WL, Wang JH, Zhao AH, Xu X, Wang YH, Chen TL et al. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood 2014; 124: 1645–1654.

    Article  CAS  Google Scholar 

  6. Akers LJ, Fang W, Levy AG, Franklin AR, Huang P, Zweidler-McKay PA . Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin. Leuk Res 2011; 35: 814–820.

    Article  CAS  Google Scholar 

  7. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005; 65: 613–621.

    CAS  PubMed  Google Scholar 

  8. Samudio I, Fiegl M, McQueen T, Clise-Dwyer K, Andreeff M . The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res 2008; 68: 5198–5205.

    Article  CAS  Google Scholar 

  9. Garrido SM, Appelbaum FR, Willman CL, Banker DE . Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 2001; 29: 448–457.

    Article  CAS  Google Scholar 

  10. Tamada M, Nagano O, Tateyama S, Ohmura M, Yae T, Ishimoto T et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res 2012; 72: 1438–1448.

    Article  CAS  Google Scholar 

  11. Chen C, Liu Y, Liu R, Ikenoue T, Guan KL, Liu Y et al. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med 2008; 205: 2397–2408.

    Article  CAS  Google Scholar 

  12. Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA et al. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood 2012; 120: 2679–2689.

    Article  CAS  Google Scholar 

  13. Spoo AC, Lubbert M, Wierda WG, Burger JA . CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007; 109: 786–791.

    Article  CAS  Google Scholar 

  14. Dillenburg-Pilla P, Patel V, Mikelis CM, Zarate-Blades CR, Doci CL, Amornphimoltham P et al. SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/Galphai/mTORC1 axis. FASEB J 2015; 29: 1056–1068.

    Article  CAS  Google Scholar 

  15. Vander Heiden MG, Cantley LC, Thompson CB . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029–1033.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

MQ was supported by the IZKF Erlangen. RJ was supported by the ELAN program of the University of Erlangen. FAK was supported by the EC FP7-funded project RADIANT. DM was supported by the IZKF Erlangen and the Max-Eder program of the Deutsche Krebshilfe. We acknowledge the assistance of the Core Unit Cell Sorting and Immunomonitoring Erlangen.

Author contributions

MB performed research, analyzed data and helped writing the manuscript. MQ, MB, FK, DS and WH performed research and analyzed data. MA collected patient material and provided patient data. AM provided patient material and helped writing the manuscript. RJ performed research, helped designing the study and writing the manuscript. DM designed the study, analyzed data and wrote the manuscript.

Author information

Authors and Affiliations

  1. Department of Internal Medicine 5, Hematology and Oncology, University of Erlangen-Nuremberg, Erlangen, Germany

    M Braun, M Qorraj, D Saul, M Aigner, A Mackensen, R Jitschin & D Mougiakakos

  2. Department of Nephropathology, Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany

    M Büttner

  3. European Molecular Biology Laboratory (EMBL), Heidelberg, Germany

    F A Klein & W Huber

Authors
  1. M Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Qorraj
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Büttner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F A Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Saul
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Aigner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Mackensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Jitschin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Mougiakakos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Mougiakakos.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Braun, M., Qorraj, M., Büttner, M. et al. CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis. Leukemia 30, 1788–1792 (2016). https://doi.org/10.1038/leu.2016.58

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2016.58

This article is cited by

Search

Advanced search

Quick links